Meeting
2022 ASCO Gastrointestinal Cancers Symposium
An observational study to evaluate RAS mutations in circulating tumor DNA after standard chemotherapies for metastatic colorectal cancer patients with tumors harboring RAS mutation: RASMEX study (JACCRO CC-17).
Authors
Naoki Izawa
Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan
Naoki Izawa , Yoshinori Kagawa , Hironaga Satake , Yu Sunakawa , Masahiro Takeuchi , Wataru Ichikawa , Masashi Fujii
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Translational Research
Clinical Trial Registration Number
UMIN000043442
DOI
10.1200/JCO.2022.40.4_suppl.TPS230
Abstract #
TPS230
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Impact of RAS and BRAF heterogeneity on the efficacy of EGFR blockade in patients with metastatic colorectal cancer.
First Author: Takeshi Yamada
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Genomic landscape of acquired resistance to targeted therapies in metastatic colorectal cancer (mCRC).
First Author: Emily Harrold
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Prospective observational study of monitoring gene alterations in plasma cell-free DNA using droplet digital PCR system during anti-EGFR antibody treatment in patients with RAS wild-type advanced colorectal cancer.
First Author: Naoki Takahashi
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Comprehensive landscape of BRAF variant classes, clonalities, and comutations in metastatic colorectal cancer using ctDNA profiling.
First Author: Benny Johnson